Exploratory, longitudinal study to define changes in muscle, tendon and neural properties after botuline neurotoxin type A (BoNT) treatment of spastic equinovarus in first-ever stroke patients: a pilot study

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513158-32-01

Enrollment

Registered

2024-12-02

Start date

2025-08-14

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spastic equinovarus in stroke patients

Brief summary

1) Primary outcome parameters measured by 3DfUS muscle volume., 2) Primary outcome parameters measured by ISA The primary outcome parameter to determine the neural contributions to hyperresistance will be derived from the fast stretch: muscle activity (root mean square (RMS) EMG [uV].

Interventions

DRUGDysport 500 U

DRUGpoudre pour solution injectable

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1) Primary outcome parameters measured by 3DfUS muscle volume., 2) Primary outcome parameters measured by ISA The primary outcome parameter to determine the neural contributions to hyperresistance will be derived from the fast stretch: muscle activity (root mean square (RMS) EMG [uV].	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026